Applied Therapeutics, Inc.

As of August 7, 2024, Applied Therapeutics, Inc. is considered overvalued with significant financial concerns, reflected in a negative ROE of -287.00% and a year-to-date stock decline of 64.96%, contrasting sharply with its peers and the S&P 500.

As of June 18, 2025, the market trend has shifted to bearish, supported by negative indicators such as daily moving averages, weekly Bollinger Bands, and monthly MACD, despite a mildly bullish weekly KST.

As of March 2022, the management team of Applied Therapeutics, Inc. includes Ms. Shoshana Shendelman as Chairman, President, CEO, and Founder, with Dr. Teena Lerner as Lead Independent Director and several Independent Directors including Mr. Leslie Funtleyder, Ms. Stacy Kanter, Mr. Joel Marcus, and Dr. Jay Skyler.

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs. As of March 2025, it has a market cap of $48.84 million and reported a net profit loss of $22 million.

As of Jun 18, Applied Therapeutics, Inc. has a market capitalization of 48.84 million, with net sales of 0.26 million and a net profit of -43.50 million over the latest four quarters. The company reported shareholder's funds of 57.01 million and total assets of 86.69 million as of Dec 24.